Gastrointestinal mesenchymal tumor genetic testing is for patients with gastrointestinal mesenchymal tumor, through the method of genetic testing, to find out whether the tumor cells undergo gene mutation, and the type of gene mutation, to help clinicians determine the cause of the disease and guide the use of drugs.
The pathogenesis of gastrointestinal mesenchymal tumors is related to gene mutations such as c-Kit and PDGFRα. Drugs targeting KIT protein and PDGFRα protein can have better efficacy on gastrointestinal mesenchymal tumors, such as imatinib and sunitinib. In addition, other mutations can be found, such as NTRK gene fusion mutations, which can be treated with targeted drugs such as larotrectinib and entrectinib.
Genetic testing is a technology that uses samples of the patient’s blood, tissues, cells, etc. to test the patient’s genetic material, including different methods such as first- and second-generation DNA sequencing, gene chips, etc., as a way of finding out whether the patient has a genetic mutation and the type of mutation, thus helping in the diagnosis and treatment of the disease.
There are different methods and testing programs for Gastrointestinal Mesenchymal Tumor Genetic Testing, and patients are advised to choose the testing method and testing program that suits their needs under the guidance of a specialist.